SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

Summary

To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing high-level evidence-based medical evidence for the use of SBRT combined with PD-1 inhibitors in the treatment of unresectable colorectal cancer liver metastasis.

Timeline

Start

2025-04-10

Primary completion

2026-06-20

Completion

2027-01-20

Drugs

Indications